# Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer

> **NCT01178944** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 35 (actual)

## Conditions studied

- Adenocarcinoma of the Gastroesophageal Junction
- Esophageal Undifferentiated Carcinoma
- Gastric Adenocarcinoma
- Gastric Squamous Cell Carcinoma
- Recurrent Esophageal Adenocarcinoma
- Recurrent Esophageal Squamous Cell Carcinoma
- Recurrent Gastric Carcinoma
- Stage IIIB Esophageal Adenocarcinoma
- Stage IIIB Esophageal Squamous Cell Carcinoma
- Stage IIIB Gastric Cancer
- Stage IIIC Esophageal Adenocarcinoma
- Stage IIIC Esophageal Squamous Cell Carcinoma
- Stage IIIC Gastric Cancer
- Stage IV Esophageal Adenocarcinoma
- Stage IV Esophageal Squamous Cell Carcinoma
- Stage IV Gastric Cancer
- Undifferentiated Gastric Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Oxaliplatin
- **DRUG:** Pralatrexate

## Key facts

- **NCT ID:** NCT01178944
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2015-01
- **Final completion:** 2015-11
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-12-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01178944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01178944, "Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01178944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*